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SUPPLEMENTARY MATERIAL 
 
 
MATERIALS AND METHODS 
 
 All animal experiments were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the National Institutes of Health (Eighth Edition, 
Revised 2010) and with the guidelines of the Animal Care and Use Committee of the University 
of Louisville, School of Medicine (Louisville, KY, USA). 
 
Isolation, culture, and transfection of c-kitPOS CPCs. CPCs were isolated from the entire heart 
(atria and ventricles) of adult male Fischer 344 rats as described. 1 The tissues were cut into 
small pieces (<1 mm3) and suspended in 15 ml of Ham’s F12 medium (Gibco) containing 1,600 
units/ml of collagenase II (Worthington Labs). After 45 min of digestion, cells were plated into 
T75 flasks containing Ham’s F12 medium supplemented with 10% fetal bovine serum 
(Seradigm), 5% horse serum (Gibco), 10 ng/ml recombinant human basic fibroblast growth 
factor (PeproTech), 10 ng/ml leukemia inhibitor factor (Millipore), 5 mU human erythropoietin 
(Sigma), 0.2 mM L-glutathione (Sigma), and 50 μg/ml porcine gelatin (Sigma). Cells were 
expanded for 5 days and subjected to immunomagnetic sorting for c-kit. Cells were then 
trypsinized, resuspended in 1 ml/107 cells of MACS buffer (Miltenyi), and then incubated with 
50 µl/107 cells of anti-c-kit antibody (H-300, Santa Cruz) for 30 min on ice. After washing, cells 
were resuspended in 240 µl/107 cells of MACS buffer and incubated with 60 µl/107 cells of 
microbeads (anti-rabbit microbeads, Miltenyi) for 15 min at 4°C. After washing, cells were 
applied onto an LS column (Miltenyi) and the positive fraction was plated into a T25 flask. The 
c-kitPOS CPCs were transfected at passage 2 or 3 with a lentiviral vector expressing GFP or 
mCherry protein. After selection with blasticidin (Invitrogen) and fluorescence-activated cell 
sorting (FACS), the GFP or mCherry positive cells were expanded and cryopreserved at 
passage 5 to 6. Then, cells were thawed, cultured, and injected into the rat heart at passages 6 to 
8. The rationale for using male donor CPCs was that the fate of transplanted CPCs can be 
tracked down by detecting Y-chromosomepos cells, although previous studies have suggested 
that bone marrow-derived mesenchymal stromal cells differ significantly between male and 
female sources, with female cells usually performing more robustly.2   
 
Characterization of c-kitPOS CPCs. Small samples of CPCs were fixed in 4% paraformaldehyde 
for 20 min at room temperature at the same passage that was used for injection. Fixed cells 
were incubated for 1 h at room temperature with an antibody against c-kit (C19), a 
hematopoietic lineage marker (CD45), an endothelial marker (CD31), or mesenchymal markers 
(CD90/105/73/29). Then, cells were incubated for 1 h at room temperature with a secondary 
antibody if the primary antibodies were not directly conjugated. FACS analysis was done with 
Accuri C6 (Accuri Cytometers) or BD LSR II (BD Biosciences) instruments.1  
 
Surgical procedures. The rat model of old MI has been described previously.3  Briefly, adult 
female Fischer 344 rats (age, 4 months; weight 175 ± 2 g) were anesthetized with ketamine (37 
mg/kg) and xylazine (5 mg/kg), intubated, and ventilated with a rodent respirator. Anesthesia 
was maintained with 1% isoflurane inhalation and body temperature was kept at 37°C with a 
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heating pad. After administration of antibiotics, the chest was opened and the heart was 
exposed. All rats underwent a 2-h occlusion of the left anterior descending coronary artery 
followed by reperfusion. Ketoprofen was given for three days after surgery (5 mg/kg). 
 
Treatment protocol. Thirty days after surgery, the animals were randomly allocated to three 
treatment groups: vehicle (control), single dose, or multiple doses (Fig. 1). Randomization was 
performed using the MS Excel random group generator. All rats received an echo-guided 
intraventricular injection, which was performed using the Vevo 2100 Imaging System 
(VisualSonics) equipped with a 20-MHz transducer, a Vevo Image Station with Injection Mount 
and micro-manipulation controls, and a Chemyx NanoJet Stereotaxic syringe pump (Chemyx 
Inc. TX). Before the procedure, rats were anesthetized with 3% isoflurane.  The anterior chest 
was shaved and the animals were placed on the imaging table in the right lateral decubitus 
position with the left lateral side facing the injection mount. Light anesthesia was maintained 
with 1% isoflurane. With the imaging transducer aligned perpendicularly to the injection 
mount, the left ventricle was initially imaged in the parasternal plane and a good 2D long-axis 
view was procured by adjusting the angle and position of the imaging table. The transducer 
was then turned 90 degrees clockwise and the left ventricle was scanned in the 2D short-axis 
and color Doppler views from apex to base to determine the optimal site for needle insertion, a 
site that did not include the infarct scar or a coronary artery. Under the guidance of a real-time 
B-mode view, a 30 G injection needle (1” length) was then carefully inserted from the left lateral 
side using the micro-manipulation controls and advanced into the center of the LV cavity.  
Rats received an infusion of CPCs (12 x 106 cells in 5 ml of DPBS (Dulbecco's phosphate-
buffered saline, Gibco) or vehicle (5 ml of DPBS) into the LV cavity with the injection pump at a 
rate of 1.25 ml/min for 4 min. The single-dose and multiple-dose groups received CPCs 
whereas the vehicle group received DPBS. Thirty-five days later, this procedure was repeated; 
rats received a second infusion of CPCs (multiple-dose group) or an infusion of DPBS (single-
dose and vehicle groups). Thirty-five days later, rats received a third infusion of CPCs 
(multiple-dose group) or another infusion of DPBS (single-dose and vehicle groups).  mCherry-
labeled CPCs were used for the 1st treatment, non-labeled CPCs for the 2nd treatment, and GFP-
labeled CPCs for the 3rd treatment. To monitor formation of new cells, in all groups 5-bromo-2’-
deoxyuridine (BrdU, Sigma) was given for 35 days after the 1st treatment and 5-iodo-2’-
deoxyuridine (IdU, Sigma) for 35 days after the 3rd treatment (both were given in the drinking 
water at a final concentration of 0.1%). At 35 days after the 3rd treatment, rats were subjected to 
hemodynamic studies and euthanized for histologic studies or PCR analysis (Fig. 1). 
Before initiating the protocol, pilot studies were conducted to identify a dose of CPCs that 
would results in LV myocardial retention similar to that observed after intracoronary infusion 
of 1 million CPCs, the dose used in our previous studies in rats.1, 3, 4  Rats underwent a 90-min 
coronary occlusion and reperfusion. Four hours after reperfusion, they received 1.0  CPCs 
(in 1 ml of DPBS) via intracoronary infusion as in our previous studies1, 3-5, 3.0, 9.0, or 12.0  
CPCs (in 5 ml of DPBS over 4 min) using echo-guided injection into the LV cavity, or 3.0x106 
CPCs i.v..  Rats were euthanized 24 h after CPC delivery and the heart was harvested to 
measure the number of CPCs in the tissue by real-time PCR.  
 
Echocardiographic studies. All echocardiographic analyses were performed by investigators 
who were blinded to treatment allocation.  Serial echocardiograms were obtained at five time-
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points: baseline (three days before coronary artery occlusion), 30 days after MI (before the 1st 
treatment), 35 days after the 1st treatment (before the 2nd treatment), 35 days after the 2nd 
treatment (before the 3rd treatment), and 35 days after the 3rd treatment (before euthanasia)(Fig. 
1 of the main manuscript). The echocardiographic studies were performed as described1, 3-5 
using a Vevo 2100 Imaging System equipped with a 20-MHz transducer. Briefly, rats were 
lightly anesthetized with 3% isoflurane. The anterior chest was shaved and the animals were 
placed in the left lateral decubitus position. A rectal temperature probe was inserted, and the 
body temperature was carefully maintained between 37.0-37.5°C with a heating pad 
throughout the study. Anesthesia was maintained with 1% isoflurane. The parasternal long-
axis and parasternal short-axis views were used to obtain 2D and M-mode images for the 
measurement of LV mass, end-diastolic and end-systolic thickness of the infarcted wall (IWTd 
and IWTs, respectively) and posterior (noninfarcted) wall (PWTd and PWTs), infarcted and 
posterior LV wall systolic thickening fraction (ThF) (IWThF and PWThF), end-diastolic and 
end-systolic LV volume (LVEDV and LVESV), stroke volume (SV), cardiac output (CO), 
ejection fraction (EF), and fractional area change (FAC).1, 3-5 The akinetic endocardial length 
(AL), expressed as a percentage of the entire LV endocardial length, was also calculated.6 
Measurements were performed according to the American Society for Echocardiography, and 
were averaged over three consecutive cardiac cycles. 
 
Hemodynamic studies. All hemodynamic analyses were performed by investigators who were 
blinded to treatment allocation.  The hemodynamic studies were conducted 35 days after the 
3rd treatment, just before euthanasia (Fig. 1). The protocol has been described. 1, 3, 5 Briefly, rats 
were anesthetized with 2-3% isoflurane, intubated, and mechanically ventilated. Anesthesia 
was maintained with 1% isoflurane and the core temperature carefully kept at 37.0°C with a 
heating pad throughout the study. A 2F microtip pressure-volume (PV) catheter (SPR-869, 
Millar Instruments) was inserted into the right carotid artery and advanced into the LV cavity. 
The right jugular vein was cannulated for fluid administration. After 30 min of stabilization, 
the PV signals were recorded continuously with an ARIA PV conductance system (Miller 
Instruments) coupled with a Powerlab/4SP A/D converter (AD Instruments), stored, and 
displayed on a personal computer. PV relations were assessed by transiently compressing the 
inferior vena cava with a cotton swab. Parallel conductance from surrounding structures was 
calculated by injecting a small bolus of 15% NaCl through the jugular vein. Hemodynamic 
indexes were calculated using the PVAN3.2software (Millar Instruments).1, 3, 5 
 
Histologic studies. The protocol for histologic analyses has been described.1, 3, 5 Briefly, after 
the hemodynamic measurements, a polyethylene catheter filled with phosphate buffer (0.2 M, 
pH 7.4) and heparin (100 IU/ml) was advanced to the ascending aorta via the right carotid 
artery. In rapid succession, the heart was arrested in diastole by injecting 1 ml of a mixture of 
cadmium chloride (100 mM)/potassium chloride (3 M) through the aortic catheter. The heart 
was then excised and perfused retrogradely with phosphate buffer for ~3 min to flush out 
residual blood in the coronary circulation, followed by perfusion with 10% neutral buffered 
formalin solution for 10 min. Perfusion pressure was maintained between 60 and 80 mmHg 
while end-diastolic pressure was kept at 8 mmHg. After perfusion-fixation, the atria and right 
ventricle were dissected from the left ventricle. The LV weight was measured; LV volume was 
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calculated as the difference between the weight of the water-filled and empty left ventricle by 
converting weight to volume (1 g H2O = 1 ml H2O).1, 3, 5, 7  
The heart was cut into four transverse slices (~2 mm thick), which were processed, 
embedded in paraffin, sectioned at 4-μm intervals, and stained with Masson’s trichrome, 
picrosirius red, or antibodies against GFP, mCherry and cell-type specific markers. Images 
were acquired digitally and analyzed using NIH ImageJ (1.48v). From the Masson’s trichrome–
stained images, morphometric parameters including total LV area, risk region area, scar area, 
and LV wall thickness in the risk and noninfarcted regions were measured in each section.1, 3, 5 
Myocardial collagen content was quantitated on picrosirius red-stained heart images acquired 
under polarized light microscopy by determining collagen density (arbitrary unit) per mm2 of 
risk region or noninfarcted region with NIH ImageJ software.1, 3  
 
Immunohistochemistry. Immunohistochemistry was performed in formalin-fixed, paraffin-
embedded, 4-µm-thick heart sections. CPC proliferation was assessed by immunofluorescent 
staining of nuclei with specific antibodies for BrdU and IdU (Santa Cruz). Myocytes were 
stained with anti-cardiac troponin I (cTnI) antibody (Santa Cruz) or with anti-α-sarcomeric 
actin (α-SA) antibody (Sigma). Myocyte membranes were stained with FITC-conjugated wheat 
germ agglutinin (WGA) (Sigma) to facilitate the identification of individual myocytes for 
analysis of myocyte cross-sectional area and myocyte density. To determine vessel density, 
heart sections were stained with specific FITC-conjugated Isolectin B4 (IB4) antibody (Sigma).8 
Triplicate immunofluorescent staining was conducted with specific anti-BrdU, anti-IdU, and 
anti-cTnI antibodies for evaluation of proliferating myocytes, and with specific anti-BrdU, anti-
IdU, and anti-Isolectin B4 antibodies for evaluation of proliferating vessels. Nuclei were stained 
with DAPI (4′,6-diamidino-2-phenylindole). 
 
Fluorescent in situ hybridization (FISH) analysis. To assess the fate of the transplanted male 
CPCs, single-labeled Y chromosome was detected by fluorescence in situ hybridization (FISH) 
according to the modified manufacturer’s protocol (ID Labs, London, ON).1, 9  4-μm-Thick 
serial tissue sections were cut from paraffin-embedded heart blocks. Heart tissue sections on 
coated slides were deparaffinized in xylene and rehydrated gradually, followed by an antigen 
retrieval procedure. After treatment with pepsin and air-drying, a denatured rat FITC-
conjugated Y chromosome probe was added to each section and covered by coverslip. After 
overnight hybridization at RT°C, the coverslip was removed and serial washings were 
performed. Male and female rat heart tissue sections were used as positive and negative 
controls, respectively, in the FISH staining procedure. Proliferation of transplanted male CPCs 
in the heart was assessed by triplicate fluorescent staining with a FITC-conjugated Y-
chromosome probe and specific anti-BrdU and anti-IdU antibodies (Santa Cruz). Myocardial 
morphology was examined with the confocal transmitted light channel’s detector (ChD) in 
which the pseudocolor selected for myocardial background in the ChD channel was gray 
white. Nuclei were counterstained with DAPI. To minimize auto fluorescence, slides were 
incubated with 0.1% Sudan Black B (Sigma), rinsed in PBS, and then mounted with ProLong 
Gold antifade reagent (Invitrogen).10 Immunohistochemical signals were imaged by confocal 
microscopy and quantitatively analyzed by Image J (1.46, NIH). In each heart, Y-
chromosomePOS nuclei, Y-chromosomePOS myocytes, Y-chromosomePOS/BrdUPOS myocytes, Y-
chromosomePOS/IdUPOS myocytes, Y-chromosomePOS/BrdUPOS/IdUPOS myocytes , total 
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myocytes, and total nuclei were counted in 25 confocal images (5 from each border zone,  10 
from the scar region, and 5 from the noninfarcted region). For Y-chromosomePOS nuclear 
analysis, an average of 1,274 nuclei was counted in a 0.354 mm2 area per rat heart (n=8/group).  
 
Measurement of transplanted cells by real-time PCR. To determine the absolute number of 
transplanted CPCs, a quantitative real-time PCR-based method was used as previously 
described.11, 12 A subset of hearts from the single-dose group (n=8) and the multiple-dose group 
(n=11) were frozen just after excision. The left ventricle was divided into two regions: the risk 
region (anterior wall and septum), which included the border zone, and the noninfarcted 
region (posterior LV wall). The tissue samples were placed in screw-cap tubes containing an 
excess volume of Buffer ATL (tissue lysis buffer) plus Proteinase K. The internal standard 
(250,000 female human peripheral mononuclear cells [hPBMCs]) was resuspended using 50 μl 
of the above tissue digestion solution and added to each tube. After overnight incubation, the 
samples were treated with RNase A (Qiagen) to prevent RNA contamination of genomic DNA. 
The DNA concentrations of the samples were measured using standard UV 
spectrophotometry. For each real-time PCR, 200 ng of genomic DNA was amplified in a 20-μl 
reaction using SYBR Green PCR Master Mix and a StepOne Plus real-time PCR machine. Each 
sample was run in triplicate and analyzed using the following sets of primers: rat Sry (for male 
rat DNA) 5'-TGCAGCGTGAAGTTGCCTCAACA-3' and 5'-
ACTGGTGTGCAGCTCTAGCCCA-3'; HLA-DMA (for human DNA) 5'-
TACAAACCTCAGCTACCTTCGTGGC-3' and 5'-AACCCAGCTGACTCTGGGTGG-3'; rat 
Gapdh (for total rat DNA) 5'-GCGCATGCCGGTCTGGCTAA-3' and 5'-
CGAGCCTTCCCCAGGTCCGA-3'. The amount of target DNA (human and male rat DNA) 
present in the PCR sample was calculated using the corresponding standard curve. The total 
number of cells present in each tissue was calculated using the following equation: F = (f*H)/h, 
where F, total number of (female) rat cells in the tissue; f, number of rat cells represented in the 
DNA sample; H, total number of human cells added to the tissue sample (i.e., 250,000); h, 
number of human cells represented in the DNA sample. The total number of male rat CPCs 
present in each tissue sample was calculated using the following equation: M = (m*F)/f, where 
M, total number of male rat cells in the tissue and m, number of rat cells presented in the DNA 
sample. The above two equations can be merged into a simplified equation: M = (m*H)/h. 
 
Statistical analysis. All data are expressed as means ± SEM.  Echocardiographic data were 
analyzed with two-way repeated-measures ANOVA followed by Student’s t-tests with 
Bonferroni correction for intra- and inter-group comparisons, as appropriate. All parametric 
data including morphometric, histologic, immunohistochemical, and hemodynamic data were 
analyzed by one-way ANOVA followed by Student’s t-tests with Bonferroni correction for 
inter-group comparisons.13-15  Mortality was analyzed by the chi-square test.  All analyses were 
conducted with SigmaStat 3.5. P values <0.05 were considered significant.  
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SUPPLEMENTARY TABLES 
Supplementary Table I: Enrollment and exclusions 
 Vehicle Single dose Multiple doses 
Initial enrollment of rats for MI studies 85 
Death after MI (all deaths were within seven days) 13  (15.3%) 
Rats assigned to group 18 24 30 
Death after either the 1st, 2nd, or 3rd infusion due to 
intrathoracic bleeding from the LV injection site 
2  
(11.1%) 
3  
(12.5%) 
4  
(13.3%) 
Completed the protocol 16 21 26 
Excluded  0 
1 
(EF drop <15 units 
after MI by 
echocardiography) 
1 
(very small scar 
size [<10% of 
risk region] by 
trichrome stain 
analysis) 
Total rats included in final analyses 16 20 25 
Hearts used for assessment of LV function   16 16 18 
Hearts used for pathology (all of these hearts were 
used for assessment of LV function) 16 12 14 
Hearts used for real-time PCR after assessment of 
LV function  0 4 4 
Hearts used for real-time PCR only 0  4 7 
Hearts excluded  from final analysis of real-time 
PCR (due to extremely high CPC number in 
myocardium) 
0 0 2  
Total hearts included for final real-time PCR data 
report 0  8 9 
 
 
 
Supplementary Table II. Body Weight and Gross Measurements 
 Initial Body 
Weight, g 
Final Body 
Wight, g 
LV weight, 
mg 
LV Chamber 
Volume, 
mm3 
Vehicle (n=16) 173.9±3.3 215.7±1.8 707.3±23.8 195.5±24.6 
Single dose (n=12) 179.7±4.8 224.3±3.7 704.6±38.2 164.5±30.3 
Multiple doses (n=14) 178.0±3.1 220.7±3.8 706.3±34.3 153.5±24.0 
Data are means ± SEM 
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Supplementary Table III. Echocardiographic data  
 
 Vehicle Control  
(n=16) 
Single dose 
(n=16) 
Multiple doses 
(n=18) 
Baseline (before MI)    
Heart rate (bpm) 326±6 327±6 325±4 
IW Thd (mm) 1.52±0.03 1.50±0.02 1.52±0.03 
IW Ths (mm) 2.44±0.04 2.37±0.05 2.42±0.05 
LVEDD (mm) 5.69±0.06 5.66±0.09 5.84±0.07 
LVESD (mm) 2.88±0.08 2.87±0.08 2.98±0.07 
PWd (mm) 1.57±0.03 1.55±0.03 1.53±0.02 
PWs (mm) 2.50±0.05 2.51±0.04 2.53±0.05 
EF (%) 79.5±0.7 78.7±0.7 79.3±0.6 
FS (%) 21.9±0.6 21.4±0.9 21.0±0.8 
FAC (%) 69.7±1.2 70.4±0.8 70.0±0.8 
LVEDV (µl) 193.6±6.4 190.2±5.9 189.5±5.2 
LVESV (µl) 39.8±2.2 40.6±2.2 39.1±1.4 
CO (ml/min) 49.9±1.3 49.0±1.3 49.4±1.4 
SV (µl) 153.9±4.9 149.5±4.2 150.4±4.3 
IW ThF (%) 65.6±2.7 68.7±2.1 69.8±2.0 
PW ThF (%) 59.1±2.4 62.9±3.1 65.2±2.5 
LV mass (mg) 523.5±16.8 509.0±18.5 536.3±12.9 
AL (%) 0 0 0 
 
30 days after MI (before treatment) 
 
Heart rate (bpm) 322±5 328±4 326±5 
IW Thd (mm) 0.75±0.04 0.73±0.04 0.69±0.04 
IW Ths (mm) 1.01±0.05 0.89±0.05 0.82±0.05 
LVEDD (mm) 6.73±0.15 6.78±0.14 7.13±0.15 
LVESD (mm) 4.11±0.21 4.23±0.21 4.70±0.22 
PWd (mm) 1.61±0.05 1.63±0.04 1.48±0.03 
PWs (mm) 2.45±0.04 2.49±0.07 2.30±0.03 
EF (%) 52.1±1.4 50.0±1.3 49.6±1.4 
FS (%) 8.6±0.8 7.6±0.6 9.4±0.5 
FAC (%) 53.7±1.9 53.1±2.7 48.5±2.0 
LVEDV (µl) 290.0±12.1 280.7±11.6 303.2±11.2 
LVESV (µl) 139.5±8.0 141.2±7.8 154.7±9.2 
CO (ml/min) 48.3±2.0 45.7±1.8 48.5±1.6 
SV (µl) 150.5±6.4 139.5±5.5 148.5±3.8 
IW ThF (%) 35.5±2.7 21.0±2.7b 18.2±2.0b 
PW ThF (%) 54.0±4.4 53.3±2.3 56.1±3.4 
LV mass (mg) 646.7±16.0 640.1±24.7 586.7±20.1 
AL (%) 28.8±2.8 28.5±1.9 28.7±2.6 
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Vehicle Control  
(n=16) 
Single dose 
(n=16) 
Multiple doses 
(n=18) 
 
35 days after 1st treatment 
Heart rate (bpm) 326±6 322±4 322±4 
IW Thd (mm) 0.64±0.04f 0.82±0.03bf 0.79±0.03bf 
IW Ths (mm) 0.79±0.05f 1.08±0.04bef 1.00±0.05bef 
LVEDD (mm) 6.67±0.15 6.38±0.12f 6.88±0.19e 
LVESD (mm) 4.37±0.20 3.90±0.18ae 4.34±0.26f 
PWd (mm) 1.55±0.08 1.63±0.04 1.56±0.04 
PWs (mm) 2.33±0.12 2.51±0.05 2.37±0.06 
EF (%) 46.7±1.7f 54.0.8±1.2bf 53.0±1.6af 
FS (%) 8.2±0.7 10.3±1.0e 9.4±0.8 
FAC (%) 48.0±1.8f 56.1±1.9a 50.9±2.3 
LVEDV (µl) 306.1±12.6 292.5±10.6 300.2±15.4 
LVESV (µl) 164.1±9.7f 135.1±7.1a 144.5±11.8e 
CO (ml/min) 46.2±2.1 50.8±2.1f 50.1±1.7 
SV (µl) 141.9±6.4 157.4±5.8f 155.7±5.4 
IW ThF (%) 21.6±2.4f 32.3±2.5bf 26.7±2.8f 
PW ThF (%) 50.3±3.4 54.9±3.2 52.4±2.8 
LV mass (mg) 609.6±34.4 610.1±18.5 637.3±20.3 
AL (%) 33.2±2.8 f 22.6±2.4b f 23.1±3.2 a f 
35 days after 2nd treatment 
Heart rate (bpm) 329±8 323±8 322±5 
IW Thd (mm) 0.61±0.03f 0.85±0.03bef 0.90±0.05bf 
IW Ths (mm) 0.75±0.05 f 1.11±0.05bf 1.21±0.06bf 
LVEDD (mm) 6.93±0.19 6.49±0.12 6.92±0.18e 
LVESD (mm) 4.70±0.21f 4.00±0.14b 4.22±0.24f 
PWd (mm) 1.59±0.07 1.56±0.04 1.55±0.03 
PWs (mm) 2.31±0.10 2.39±0.05 2.49±0.03 f 
EF (%) 44.4±2.0f 54.4±1.0bf 57.0±1.7bf 
FS (%) 8.7±0.9 9.9±1.0 12.2±0.8bf 
FAC (%) 45.3±1.9 f 53.8±2.0b 53.8±2.0bf 
LVEDV (µl) 313.3±16.2 312.7±12.4e 311.4±13.0 
LVESV (µl) 175.7±12.5 f 143.0±7.5a 136.5±10.6af 
CO (ml/min) 45.0±2.4 54.9±2.5bf 56.2±1.8bf 
SV (µl) 137.6±7.8 169.6±6.5bf 174.9±5.3bf 
IW ThF (%) 22.4±2.8 f 30.2±2.1af 34.7±2.6bf 
PW ThF (%) 45.0±4.3  53.9±3.8 61.4±2.0b 
LV mass (mg) 639.3±32.7 627.4±26.7 662.3±19.0 
AL (%) 35.9±1.7 f 22.6±1.7b f 18.2±2.5 b f 
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Vehicle Control  
(n=16) 
Single dose 
(n=16) 
Multiple doses 
(n=18) 
Final echo (35 days after 3rd treatment) 
Heart rate (bpm) 330±8 323±8 322±5 
IW Thd (mm) 0.54±0.03f 0.88±0.03bef 1.01±0.05bcf 
IW Ths (mm) 0.65±0.04f 1.13±0.05bf 1.42±0.08bdf 
LVEDD (mm) 6.96±0.16 6.74±0.13  6.84±0.18 f 
LVESD (mm) 4.96±0.18f 4.09±0.16b 4.02±0.20be f 
PWd (mm) 1.58±0.09 1.64±0.04 1.56±0.03 e 
PWs (mm) 2.19±0.12 e 2.51±0.05a 2.52±0.04bf 
EF (%) 40.1±1.9f 54.7±0.8bf 62.5±1.5bdf 
FS (%) 7.9±0.9 10.2±0.9 f 12.8±0.9bcf 
FAC (%) 41.7±2.5f 54.8±1.6b 59.8±1.5bcf 
LVEDV (µl) 329.7±18.5e 328.0±11.3f 343.0±18.2f 
LVESV (µl) 196.9±12.0f 149.1±6.9b 130.4±10.6bf 
CO (ml/min) 43.6±3.2 58.1±2.2bf 69.9±3.8bcf 
SV (µl) 132.7±10.2 178.8±5.3bf 212.5±10.0bdf 
IW ThF (%) 20.1±2.4f 29.1±2.2bef 40.5±3.2bcf 
PW ThF (%) 38.9±3.4f 54.1±2.2b 61.4±2.3bc 
LV mass (mg) 634.8±43.6 695.6±27.2 692.0±21.4 
AL (%) 37.0±2.6 f 22.7±2.0b f 15.1±2.5 b cf 
 
Data are means ± SEM. 
 
IW Thd, infarcted wall thickness at end-diastole; IW Ths, infarcted wall thickness at end-systole; LVEDD, left ventricular 
end-diastolic diameter; LVESD, left ventricular end-systolic diameter; PWd, posterior wall thickness at end-diastole; PWs, 
posterior wall thickness at end-systole; EF, ejection fraction; FS, fractional shortening; FAC, fractional area change; LVEDV, 
left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; CO, cardiac output; SV, stroke volume; 
IW ThF, infarcted wall systolic thickening fraction; PW ThF, posterior wall systolic thickening fraction; AL, akinetic 
endocardial length (expressed as a percentage of the LV endocardial length). a, P<0.05, and b, P<0.01 vs. vehicle; c, P<0.05, 
and d, P<0.01 vs. single dose; e, P<0.05, and f, P<0.01 vs after MI;  
   
Supplementary Materials (CIRCRES_2016_308937) 
12 
 
Supplementary Table IV. Hemodynamic data 
 Vehicle (Control) 
(n=16) 
Single dose 
(n=16) 
Multiple doses 
(n=18) 
Heart rate (bpm) 324±6 330±6 335±4 
LV end-diastolic volume (µL) 295.1±17.7 225.4±18.6 a 193.2±14.2b 
LV end-systolic volume (µL) 170.9±8.1 101.7±6.4b 73.7±5.4bd 
LV end-systolic pressure 100.5±3.2 111.2±2.6 a 112.4±2.3 b 
LV end-diastolic pressure 10.9±0.7 8.3±0.2b 7.1±0.4bc 
Ejection fraction (%) 46.8±1.1 60.3±1.0b 65.7±1.1bd 
dP/dtmax (mmHg/sec) 6365±294 7614±203b 7983±135b 
dP/dtmin (mmHg/sec) -6334±249 -7688±275b -8175±169b 
P@dP/dtmax (mmHg) 70.0±3.6 78.9±1.5 a 78.8±2.1 a 
V@dP/dtmax (µL) 286.1±16.6 219.2±16.7 b 175.4±12.3 bc 
V@dP/dtmin (µL) 167.1±8.3 102.9±6.2 b 74.2±5.9 bd 
Tau_w (msec) 12.7±0.4 10.9±0.4 b 10.4±0.3b 
PAMP (mWatts/µL2) 7.6±0.6 16.1±2.0b 19.4±1.7b 
Ees 0.62±0.05 0.90±0.06b 1.19±0.08bd 
PRSW 62.4±5.3 72.6±5.5 98.1±6.9bd 
Emax 1.47±0.27 1.86±0.18 2.63±0.37a 
dP/dt-EDV 25.5±2.2 42.0±6.1a 53.2±4.3b 
dP/dtmax-EDV 22.6±1.5 36.8±3.2b 45.1±3.2b 
Data are means ± SEM. 
Tau_w, Tau-Weiss method; PAMP, preload-adjusted maximal power; Ees, end-systolic elastance; PRSW, preload-
recruitable stroke work; Emax, maximal elastance during a cardiac circle; EDV, end-diastolic volume. a, P<0.05, and b, 
P<0.01 vs. vehicle; c, P<0.05, and d, P<0.01 vs. single dose. 
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Supplementary Table V. Morphometric data 
 Vehicle Control  
(n=16) 
Single dose 
(n=12) 
Multiple 
doses 
(n=14) 
LV weight (mg, postmortem)  707.3±23.8 704.6±38.2 706.3±34.3 
Total LV wall area (mm2) 30.7±1.5 31.9±2.1 32.7±1.3 
Risk region area (mm2) 14.6±1.1 15.6±1.5 16.1±1.8 
Non-risk region area (mm2) 16.1±1.2 16.3±1.7 16.5±1.4 
Scar area (mm2) 7.1±0.7 6.2±0.7 5.2±0.6a 
Risk region weight (mg) 336.3±24.9 341.9±27.0 345.6±34.8 
Scar weight (mg) 166.6±18.8 136.2±15.0 115.7±16.4 
Viable tissue weight in non-risk region (mg) 371.0±21.9 362.7±36.9 360.7±30.6 
Viable tissue weight in risk region (mg) 169.6±10.8 205.7±18.0 229.9±25.4a 
Total viable tissue weight (mg) 540.6±19.8 568.3±26.3 590.6±20.2 
Risk (% of total LV) 47.5±2.9 49.0±3.5 48.8±4.2 
Scar (% of risk region) 48.5±2.3 35.1±3.9a 32.0±3.0b 
Scar (% of LV) 23.3±2.1 18.9±1.4 15.6±1.5b 
Viable tissue (% of risk region) 51.5±2.3 60.6±2.9a 66.7±2.9b 
Average IW thickness (mm) 0.92±0.07 1.18±0.06a 1.41±0.07b 
IW thickness (mm) 0.67±0.06 0.82±0.12 0.96±0.09a 
NIW thickness (mm) 2.06±0.12 2.12±0.12 1.99±0.13 
Data are means ± SEM. 
IW thickness, infarcted wall thickness; NIW thickness, non-infarcted wall thickness. a, P<0.05, 
and b, P<0.01 vs. vehicle; c, P<0.05, and d, P<0.01 vs. single dose. 
 
 
 
Supplementary Table VI. Number of male CPCs at 105 days after the 1st treatment 
Group CPCs/heart 
Rats with detectable CPCs 
Single dose (n=5) 3,330 ± 931 
Multiple dose (n=7) 5,078 ± 1,409 
All rats (included rats no detectable CPCs) 
Single dose (n=8) 2,081 ± 1,060 
Multiple dose (n=9) 3,949 ± 1,310 
Data are means ± SEM. 
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